AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, Wednesday announced positive data from Phase 2b RENOIR study of rosnilimab for the treatment of rheumatoid arthritis (RA). The trial met its primary goal. The company's stock was more than 20 percent up in pre-market.
In the study, patients were randomized to receive either 100 mg of rosnilimab every four weeks, 400 mg every four weeks, 600 mg every two weeks or placebo. The trial achieved its primary endpoint of the mean change from baseline in DAS-28 CRP at Week 12 across all rosnilimab doses versus placebo. DAS-28 CRP or Disease Activity Score 28 using C-reactive protein is a clinical measure used to assess the activity of rheumatoid arthritis.
Additionally, nearly 50 percent reduction in the mean CRP from baseline, a measure of inflammation, was observed in rosnilimab-treated patients through the entire trial period that was not observed on placebo. Further, rosnilimab was safe and well tolerated with similar adverse event rates versus placebo.
The company expects to report full Week 28 and additional translational RA data in the second quarter of 2025. AnaptysBio shares, closed at $12.38, down 4.81 percent on Tuesday, have been trading in the range of $12.21 - $41.31 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.